A new Executive Order from the Trump Administration could significantly accelerate the development and approval of psychedelic-assisted therapies in the United States, according to Jim Maguire, co-founder of Government Market Strategies.
Maguire outlined how the order creates a coordinated effort across federal agencies to speed up research, clinical trials, and regulatory decisions for psychedelic-based mental health treatments.
FDA to fast-track breakthrough therapies
One of the main changes directs the U.S. Food and Drug Administration to create National Priority Vouchers. These vouchers are designed to shorten the time it takes to review and approve breakthrough medicines.
Maguire said this could significantly reduce delays for promising psychedelic treatments that show strong clinical results.
Easier approvals for research
The order also instructs the Drug Enforcement Administration to speed up permissions for doctors and researchers studying Schedule I substances, including psychedelics.
This would make it easier to run clinical trials and expand scientific research that has historically been tightly restricted.
Funding redirected to state programs
The U.S. Department of Health and Human Services will redirect $50 million from ARPA-H, the Advanced Research Projects Agency for Health, to support state programs developing psychedelic-assisted therapy.
Maguire noted this signals a shift from research only toward building real-world treatment systems.
Review of substances with late-stage evidence
Another directive asks the U.S. Department of Justice and HHS to review Schedule I substances that already have Phase 3 clinical trial data for serious mental illness.
If the evidence is strong enough, these substances could be considered for rescheduling, which would allow medical use under federal law.
Early companies already benefiting
According to Jim Maguire, three organizations have already received National Priority Vouchers. These include Compass Pathways, Usona Institute, and Transcend Therapeutics.
He said these designations will help speed up clinical trials and improve communication with regulators.
Veterans Affairs could lead early rollout
Maguire also highlighted the U.S. Department of Veterans Affairs as a key system ready to deliver these therapies once they are approved.
He pointed to more than 20 active studies, hundreds of trained clinicians, and an existing care infrastructure that could allow rapid implementation for veterans, especially those with PTSD.
Approval timeline could shorten, but challenges remain
Based on the current momentum, Maguire said FDA approval for one or more psychedelic therapies this year now appears more likely.
However, he also warned that widespread access will take longer. Health systems will need to build infrastructure, train providers, and work through insurance coverage and state regulations.
Safety and patient protections emphasized
Maguire stressed that expanding psychedelic-assisted therapy must include strong safeguards.
These treatments can carry risks such as anxiety, psychological distress, or adverse psychiatric reactions. He also noted that vulnerable patients with severe mental illness require careful screening and oversight.
He said protections should include strict medical evaluations, clear informed consent, ethics training for providers, strong credentialing systems, and in some cases independent monitoring during treatment.
A rapidly evolving policy shift
Jim Maguire described the Executive Order as a major step toward integrating psychedelic-assisted therapy into mainstream mental health care.
While he sees faster progress toward approval, he emphasized that safe and responsible rollout will depend on careful regulation, strong clinical standards, and coordinated implementation across federal and state systems.